Citations

Clear

4847 citation(s) found for "Yu, Eric".

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider
Unger, Julia , Putrik, Polina , Buttgereit, Frank , Aletaha, Daniel , Bianchi, Gerolamo , Čikeš, Nada, Dias, João Madruga , Falzon, Louise , Gossec, Laure , Matteson, Eric L. , Wiek, Dieter , Zink, A. , Dejaco, Christian , Stamm, Tanja A , Dejaco, Christian , Gossec, Laure , Buttgereit, Frank , Bijlsma, J. W. J. , Boonen, Annelies E. R. C. H. , Finckh, Axel , Kvien, Tore Kristian , Sivera, Francisca , Szekanecz, Zoltán , Ramiro, Sofía

Mayo Clinic

RMD Open | December 6, 2018 | Volume: 4 | Issue: 2 | Pages: e000756

10.1136/rmdopen-2018-000756 | PMID 30714580 Get It

Objective To summarise the available information on physician workforce modelling, to develop a rheumatology workforce prediction risk of bias tool and to apply it to existing studies in rheumatology. Methods A systematic literature review (SLR) was performed in key electronic databases (1946–2017) comprising an update of an SLR in rheumatology and a hierarchical SLR in other medical fields. Data on the type of workforce prediction models and the factors considered in the models were extracted. Key general as well as specific need/demand and supply factors for workforce calculation in rheumatology were identified. The workforce prediction risk of bias tool was developed and applied to existing workforce studies in rheumatology. Results In total, 14 studies in rheumatology and 10 studies in other medical fields were included. Studies used a variety of prediction models based on a heterogeneous set of need/demand and/or supply factors. Only two studies attempted empirical validation of the prediction quality of the model. Based on evidence and consensus, the newly developed risk of bias tool includes 21 factors (general, need/demand and supply). The majority of studies revealed high or moderate risk of bias for most of the factors. Conclusions The existing evidence on workforce prediction in rheumatology is scarce, heterogeneous and at moderate or high risk of bias. The new risk of bias tool should enable future evaluation of workforce prediction studies. This review informs the European League Against Rheumatism points to consider for the conduction of workforce requirement studies in rheumatology.
EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology
Dejaco, Christian , Putrik, Polina , Unger, Julia , Aletaha, Daniel , Bianchi, Gerolamo , Čikeš, Nada, Gossec, Laure , Dias, João Madruga , Matteson, Eric L. , Wiek, Dieter , Zink, A. , Buttgereit, Frank , Stamm, Tanja A , Dejaco, Christian , Gossec, Laure , Buttgereit, Frank , Bijlsma, J. W. J. , Boonen, Annelies E. R. C. H. , Finckh, Axel , Kvien, Tore Kristian , Sivera, Francisca , Szekanecz, Zoltán , Ramiro, Sofía

Mayo Clinic

RMD Open | December 6, 2018 | Volume: 4 | Issue: 2 | Pages: e000780

10.1136/rmdopen-2018-000780 | PMID 30714579 Get It

Objective Current methods used for forecasting workforce requirements in rheumatology are disparate, as are the parameters incorporated into workforce projection studies. The objective of these European League Against Rheumatism (EULAR points to consider (PTC) is to guide future workforce studies in adult rheumatology in order to produce valid and reliable manpower estimates. Methods The EULAR Standardised Operating Procedures were followed. A multidisciplinary task force with experts including patients with rheumatic diseases from 11 EULAR countries and the USA was assembled. A systematic literature review (SLR) was conducted to retrieve workforce models in rheumatology and other medical fields. PTC were based on expert opinion informed by the SLR, followed by group discussions with consensus obtained through informal voting. The level of agreement with the PTC was voted anonymously. Results A total of 10 PTC were formulated. The task force recommends models integrating supply (=workforce available in rheumatology), demand (=health services requested by the population) and need (=health services that are considered appropriate to serve the population). In general, projections of workforce requirements should consider all factors relevant for current and future workload in rheumatology inside and outside of direct patient care. Forecasts of workforce supply should consider demography and attrition of rheumatologists, as well as the effects of new developments in healthcare. Predictions of future need/demand should take demographic, sociocultural and epidemiological development of the population into account. Conclusion These EULAR-endorsed PTC will provide guidance on the methodology and the parameters to be applied in future national and international workforce requirement studies in rheumatology.
Home Health Care Availability and Discharge Delays in Children With Medical Complexity
Maynard, Roy, Cady, Rhonda , Jacob, Abraham, Ouellette, Yves , Podgorski, Heather, Schiltz, Brenda , Schwantes, Scott, Wheeler, William , Christensen, Eric , Jacob, Abraham

Mayo Clinic

Pediatrics | December 3, 2018 | Volume: 143 | Issue: 1 | Pages: No page available

10.1542/peds.2018-1951 | PMID 30509929 Get It

BACKGROUND: An increasing proportion of pediatric hospital days are attributed to technology-dependent children. The impact that a pediatric home care nursing (HCN) shortage has on increasing length of hospital stay and readmissions in this population is not well documented. METHODS: We conducted a 12-month multisite prospective study of children with medical complexity discharging with home health. We studied the following 2 cohorts: new patients discharging for the first time to home nursing and existing patients discharging from the hospital to previously established home nursing. A modified delay tool was used to categorize causes, delayed discharge (DD) days, and unplanned 90-day readmissions. RESULTS: DD occurred in 68.5% of 54 new patients and 9.2% of 131 existing patients. Lack of HCN was the most frequent cause of DD, increasing costs and directly accounting for an average length of stay increase of 53.9 days (range: 4–204) and 35.7 days (3–63) for new and existing patients, respectively. Of 1582 DDs, 1454 (91.9%) were directly attributed to lack of HCN availability. DD was associated with younger age and tracheostomy. Unplanned 90-day readmissions were due to medical setbacks (96.7% of cases) and occurred in 53.7% and 45.0% of new and existing patients, respectively. CONCLUSIONS: DD and related costs are primarily associated with shortage of HCN and predominantly affect patients new to HCN. Medical setbacks are the most common causes of unplanned 90-day readmissions. Increasing the availability of home care nurses or postacute care facilities could reduce costly hospital length of stay.
Longitudinal Occurrence and Predictors of Patient‐Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case–Control Study
Challa, Divya N. V., Kvrgic, Zoran, Crowson, Cynthia S. , Matteson, Eric L. , Mason, Thomas G. , Michet, Clement J. , Wright, Kerry , Davis, John M. , Schaffer, Daniel E, Wright, Kerry A, Davis, John M , Mason, Thomas G., Schäffer, Daniel E.

Mayo Clinic

Arthritis Care & Research | November 30, 2018 | Volume: 72 | Issue: 1 | Pages: 18-26

10.1002/acr.23819 | PMID 30506552 Get It

ObjectiveTo identify longitudinal predictors of discordance between patients with rheumatoid arthritis (RA) and their health care providers, where patient global assessment of disease activity is substantially higher than provider global assessment.MethodsThis retrospective case–control study included 102 cases with positive discordance (i.e., ≥25 mm between patient and provider global assessments) and 102 controls without discordance who were matched for age, sex, RA duration, and Clinical Disease Activity Index (CDAI) score. Data were collected at the baseline visit (date of diagnosis or earliest available visit), the index visit (participation in a previous cross‐sectional study), and at up to 11 additional visits before the index visit. Data included patient characteristics, disease activity measures, Disease Activity Score in 28 joints (3‐variable) using the C‐reactive protein level (DAS28‐CRP), and medications. Data were analyzed by using linear and logistic regression models with smoothing splines for nonlinear trends.ResultsOverall, the mean age was 63 years, 75% of patients were female, and the mean RA duration was 10 years. Compared with controls, cases had higher rates of discordant visits during the 4 years before the index visit, and they had a higher CDAI score and DAS28‐CRP earlier in the disease course. Cases more frequently had antinuclear antibodies, nonerosive disease, prior depression, or prior use of antidepressants or fibromyalgia medications. Disease‐modifying medication use was not different between cases and controls.ConclusionThe findings inform new hypotheses about the relationships of disease activity and antinuclear antibodies to the later occurrence of positive discordance among patients with RA.
What the HEC? Physician variation and attainable compliance targets in antiemetic prophylaxis.
Roeland, Eric , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Binder, G. , Sebastiani, Silvia , Schmerold, Luke, Papademetriou, Eros , Navari, Rudolph M. , Leblanc, Thomas , Roeland, Eric J , Nipp, Ryan David , Sebastiani, Silvia, Potluri, Ravi C.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 74-74

10.1200/jco.2018.36.34_suppl.74 Get It

74 Background: U.S. National Antiemetic Guidelines recommend upfront triple prophylaxis (NK1 receptor antagonist (RA) + 5HT3 RA + dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC), including carboplatin AUC ≥ 4 per 2017 guidelines. While existing data show gaps in guideline compliance, variation between individual physicians is less studied, and a realistic target compliance rate remains unknown. Methods: In a large electronic health record database (IBM Explorys), we identified HEC courses of therapy initiated from 2012 to 2017. Guideline compliance was defined as triple prophylaxis at chemotherapy initiation. Patient courses for ≥ 7 day cycles of cisplatin or anthracycline + cyclophosphamide (AC), or carboplatin (≥ 14 day cycles as a proxy for AUC ≥ 4) were ascribed to oncologists based on encounter frequency. We then ranked physicians treating ≥ 5 HEC courses and evaluated guideline compliance and individual physician variation. Results: In total, 10,074 HEC courses were identified and attributed to 451 unique physicians. Overall antiemetic guideline compliance with cisplatin and AC averaged 68% and 81% respectively. When ranked by compliance, the top 20% of physicians were 2.5 - 1.5 times as compliant as the bottom 20% (cisplatin 100% vs 40%; AC 100% vs 67%). For cisplatin, 32% of physicians had > 90% compliance; the remaining 68% were evenly distributed from 0 - 90%. For AC, 56% of physicians had > 90% compliance, and another 14% had 80 - 90%; the remaining 30% were evenly distributed. For carboplatin, 62% of physicians had ≤ 10% compliance, and another 17% had 11 - 20%; however, the majority of these data preceded guideline inclusion of carboplatin AUC ≥ 4 as HEC. Rates were independent of course volume per physician. Conclusions: Considerable physician-level variation exists in triple antiemetic prophylaxis guideline adherence for HEC. Hundreds of physicians had > 90% compliance with guidelines, suggesting 90% is a realistic target. However, the majority exhibited substantial gaps in NK1 RA use in HEC, placing patients unnecessarily at risk for CINV. Interventions are needed to bolster triple antiemetic prophylaxis in HEC, perhaps especially for carboplatin.
Inpatient hospitalization costs associated with nausea and vomiting among patients with cancer.
Roeland, Eric , Ruddy, Kathryn J. , Binder, G. , Bailey, William L., Amari, Diana T., Kanakamedala, Hemanth, Navari, Rudolph M. , Roeland, Eric J , Nipp, Ryan David

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 112-112

10.1200/jco.2018.36.34_suppl.112 Get It

112 Background: Reducing hospitalizations for chemotherapy-related toxicities represents an opportunity to improve both the quality and cost of cancer treatment. Nausea and vomiting (NV) account for almost 10% of “avoidable” toxicity-related post-chemotherapy hospitalizations (2016 Medicare data). We sought to evaluate the event cost of NV-related hospitalizations among patients with cancer from a US payer perspective. Methods: From a large US claims database (Truven MarketScan), we identified hospitalizations with NV as the primary diagnosis and cancer as a secondary diagnosis (01/2011-06/2017). This method increases specificity for NV as the principal hospitalization factor, while underreporting the prevalence of NV as a contributory factor. To determine event costs, we evaluated hospital and other reimbursement during the hospitalization. To explore subgroup differences, we stratified results by tumor type, payer type, admission route, receipt of highly emetogenic chemotherapy (HEC; 2017 definition includes carboplatin AUC ≥4) and antiemetic prophylaxis. We adjusted all costs to 2017 US dollars. Results: Among 918,192 hospitalizations involving cancer, we identified 80,995 with both NV and a cancer diagnosis code. Of these, 5,293 had NV as the primary diagnosis and 62 lacked cost data. Patients (mean age = 57.7±16.2) were 67% female. Median hospital length of stay was 4 days and mean cost per hospitalization was $15,085. Non-Medicare admissions (82%) had a higher mean cost vs. Medicare ($15,737 vs. $12,111, p < 0.01). We found < $1,000 difference between the highest and lowest cost per hospitalization among the 6 most common tumor types. We found the 65% of patients with a chemotherapy claim ≤30 days prior to hospitalization had costs of $13,882 per event. Among the 45% of chemotherapies that were HEC, > 50% lacked an NK1 receptor antagonist as prophylaxis. Conclusions: The average cost of NV-related hospitalizations among patients with cancer exceeds $15,000 per event, highlighting the need to effectively address this symptom. Roughly half the hospitalizations involved HEC, with over half of those patients not receiving guideline-based antiemetic prophylaxis.
Detecting potential pleiotropy across cardiovascular and neurological diseases using univariate, bivariate, and multivariate methods on 43,870 individuals from the eMERGE network
Zhang, Xinyuan , Veturi, Yogasudha , Bone, William P. , Lucas, Anastasia, Hebbring, Scott J. , Stanaway, Ian B. , Jarvik, Gail P. , Crosslin, David R. , Larson, Eric B. , Sleiman, Patrick , Fasel, David , Wei, Wei‐Qi, Schaid, Daniel J. , Ritchie, Marylyn D. , Jarvik, Gail P , Wei, Wei-Qi , Verma, Shefali S. , Verma, Anurag , Denny, Joshua C. , Rasmussen‐Torvik, Laura J. , Pendergrass, Sarah A. , Smoller, Jordan W. , Håkonarson, Håkon , Weng, Chunhua , Kullo, Iftikhar J. , Chung, Wendy K.

Mayo Clinic

Biocomputing 2019 | November 28, 2018 | Volume: No volume available | Issue: No issue available | Pages: 272-283

10.1142/9789813279827_0025 Get It

Is Enhancement the Price of Prevention in Human Gene Editing?
Conley, John M., MacKay, Douglas , Kuczynski, Kristine J. , Cadigan, R. Jean , Meagher, Karen M. , Juengst, Eric T. , Henderson, Gail E. , Walker, Rebecca L. , Saylor, Katherine Witte , Waltz, Margaret

Mayo Clinic

The CRISPR Journal | November 26, 2018 | Volume: 1 | Issue: 6 | Pages: 351-354

10.1089/crispr.2018.0040 | PMID 31021238 Get It

Abstract New gene-editing tools challenge conventional policy proscriptions of research aimed at either human germline gene editing or human enhancement by potentially lowering technical barriers to both kinds of intervention. Some recent gene-editing reports have begun to take up the prospect of germline editing, but most experts are in broad agreement that research should prioritize medical applications over attempts to enhance human traits. However, there is little consensus about what counts as human enhancement in this context, or how to deal with the issues it flags. Moreover, several influential reports interpret medical applications to include disease prevention as well as treatment as a goal for gene-editing research. This challenges the current policy consensus because using gene editing to prevent disease would incidentally facilitate human enhancement applications in a variety of ways. If such research efforts are penalized by policy concerns about enhancement, then their preventive health benefits could be lost. To avoid being caught off guard by such challenges, science policy makers will need to think more carefully about what “prevention” might mean in the gene-editing context, and develop research governance that can anticipate and address the human enhancement concerns it will raise. To accomplish the latter, the scope of policy making will need to expand from its narrow focus on human clinical trials to engage with basic researchers driving the translational pipeline toward preventive gene editing and the science policy makers who have to address its “off-label” uses.
2169. Map the Gap: A Novel Approach Using Big Data to Determine the State of the Infectious Diseases Workforce and Fecal Transplant Centers with Regards to Clostridium Difficile Infection
Shah, Aditya , Stone, Eric C., O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S640-S640

10.1093/ofid/ofy210.1825 Get It

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Théry, Clotilde , Witwer, Kenneth W. , Aïkawa, Elena , Alcaraz, María José , Anderson, Johnathon D. , Andriantsitohaina, Ramaroson , Antoniou, Anna , Arab, Tanina , Archer, Fabienne , Atkin‐Smith, Georgia K. , Ayre, D. Craig , Bach, Jean‐Marie , Bachurski, Daniel , Baharvand, Hossein , Balaj, Leonora , Baldacchino, Shawn , Bauer, Natalie , Baxter, Amy A. , Bebawy, Mary , Beckham, Carla, Zavec, Apolonija Bedina, Benmoussa, Abderrahim , Berardi, Anna C. , Bergese, Paolo , Bielska, Ewa , Blenkiron, Cherie , Bobis‐Wozowicz, Sylwia , Boilard, Éric , Boireau, Wilfrid , Bongiovanni, Antonella , Borràs, Francesc E. , Bösch, Steffi , Boulanger, Chantal M. , Breakefield, Xandra O. , Breglio, Andrew , Brennan, Meadhbh Á. , Brigstock, David R. , Brisson, Alain , Broekman, Marike L. D. , Bromberg, Jacqueline , Bryl‐Górecka, Paulina , Burger, Dylan , Busatto, Sara , Buschmann, Dominik , Buzás, Edit I. , Byrd, James Brian , Carter, David R. F. , Caruso, Sarah , Chamley, Lawrence W. , Cheng, Lesley , Chin, Andrew R., Clayton, Aled , Clerici, Stefano Piatto , Cocks, Alex, Cocucci, Emanuele , Coffey, Robert J., Cordeiro‐da‐Silva, Anabela , Couch, Yvonne , Coumans, Frank A. W., Coyle, Beth , Crescitelli, Rossella , Criado, Miriã Ferreira, D’Souza‐Schorey, Crislyn , Chaudhuri, Amrita Datta , Candia, Paola de , Santana, Eliezer F De , Wever, Olivier De , Portillo, Hernando A. del , Demaret, Tanguy , Deville, Sarah , Devitt, Andrew , Dhondt, Bert , Vizio, Dolores Di , Rubio, Ana Paula Domínguez , Dourado, Maurício Rocha , Driedonks, Tom A. P. , Duarte, Filipe V. , Duncan, Heather M. , Eichenberger, Ramon M. , Ekström, Karin M. , Andaloussi, Samir EL , Élie-Caille, Céline , Erdbrügger, Uta , Fatima, Farah , Fish, Jason E. , Flores‐Bellver, Miguel , Försönits, András, Frelet‐Barrand, Annie , Fricke, Fabia , Fuhrmann, Gregor , Gámez‐Valero, Ana , Gardiner, Chris , Gärtner, Kathrin , Gaudin, Raphaël , Gho, Yong Song , Giebel, Bernd , Gilbert, Caroline , Gimona, Mario , Giusti, Ilaria , Goberdhan, Deborah C. I. , Görgens, André , Gorski, Sharon M. , Greening, David W. , Gross, Julia Christina , Gualerzi, Alice , Gupta, Gopal N. , Gustafson, Dakota , Handberg, Aase , Haraszti, Reka A. , Harrison, Paul , Hegyesi, Hargita , Hendrix, An , Hill, Andrew F. , Hochberg, Fred H. , Hoffmann, Karl F. , Holder, Beth , Holthöfer, Harry , Hosseinkhani, Baharak , Hu, Guoku , Huang, Yiyao , Huber, Veronica , Hunt, Stuart , Ibrahim, Ahmed , Ikezu, Tsuneya , Inal, Jameel M. , Işın, Mustafa , Ivanova, Alena , Jackson, Hannah K. , Jacobsen, Søren , Jay, Steven M. , Jayachandran, Muthuvel , Jenster, Guido , Jiang, Lanzhou , Johnson, Suzanne M. , Jones, Jennifer , Jong, Ambrose, Jovanović‐Talisman, Tijana , Jung, Stephanie , Kalluri, Raghu , Kano, Shin‐ichi , Kaur, Sukhbir , Kawamura, Yumi , Keller, Evan T. , Khamari, Delaram , Khomyakova, Elena , Kierulf, Peter, Kim, Kwang Pyo , Kislinger, Thomas , Klingeborn, Mikael , Klinke, David J. , Kornek, Miroslaw , Kosanović, Maja , Kovács, Árpád Ferenc , Krämer‐Albers, Eva‐Maria , Krause, Mirja, Kurochkin, Igor V. , Kuypers, Sören , Laitinen, Saara , Langevin, Scott M. , Languino, Lucia R. , Lässer, Cecilia , Laurent, Louise C. , Lázaro‐Ibáñez, Elisa , Lay, Soazig Le , Lee, Myung‐Shin , Lee, Yi , Lemos, Débora S., Lenassi, Metka , Leszczynska, Aleksandra , Li, Isaac T. S. , Liao, Ke , Libregts, Sten F.W.M. , Ligeti, Erzsébet , Lim, Rebecca , Lim, Sai Kiang , Linē, Aija , Linnemannstöns, Karen, Llorente, Alicia , Lorenowicz, Magdalena J. , Lőrincz, Ákos M. , Lovett, Jason , Lowry, Michelle C., Loyer, Xavier , Lu, Quan , Łukomska, Barbara , Lunavat, Taral R. , Marcilla, Antonio , Mariani, Jacopo , Mariscal, Javier , Martens‐Uzunova, Elena S. , Martín‐Jaular, Lorena , Martínez, Maria Carmen , Martins, Vilma R. , Mathieu, Mathilde , Mathivanan, Suresh , Maugeri, Marco , McGinnis, Lynda K. , McVey, Mark J. , Meckes, David G. , Meehan, Katie , Jørgensen, Maléne Møller , Morhayim, Jess , Muraca, Maurizio , Musante, Luca , Mussack, Veronika , Muth, Dillon C. , Myburgh, Kathryn H. , Najrana, Tanbir , Nawaz, Muhammad , Nazarenko, Irina , Nejsum, Peter , Néri, Christian , Nolan, John P. , Hoen, Esther Nm Nolte-'t, Hooten, Nicole Noren , O’Grady, Tina , Ochiya, Takahiro , Olivier, Martin , Ortíz, Alberto , Ortiz, Luis A. , Osteikoetxea, Xabier , Østergaard, Ole , Ostrowski, Matías , Pegtel, D. Michiel , Peinado, Héctor , Perut, Francesca , Pfaffl, Michael W. , Phinney, Donald G. , Pieters, Bartijn C. H. , Pink, Ryan , Pisetsky, David S. , Strandmann, Elke Pogge von , Polakovičová, Iva , Poon, Ivan K. H. , Powell, Bonita H. , Prada, Ilaria , Pulliam, Lynn , Quesenberry, Peter J. , Radeghieri, Annalisa , Raffaı̈, Robert L. , Rak, Janusz , Ramirez, Marcel I. , Raposo, Graça , Rayyan, Morsi , Ricklefs, Franz , Roberts, David D. , Rodrigues, Sílvia C. , Rohde, Eva , Rome, Sophie , Rouschop, Kasper M.A. , Rughetti, Aurelia , Russell, Ashley E. , Sahoo, Susmita , Salas‐Huenuleo, Edison , Sánchez, Catherine , Saugstad, Julie A. , Saul, Meike J. , Schneider, Raphaël , Schøyen, Tine Hiorth , Scott, Aaron , Shahaj, Eriomina , Sharma, Shivani , Shatnyeva, Olga , Shekari, Faezeh , Shelke, Ganesh Vilas , Shiba, Kiyotaka , Siljander, Pia , Silva, Andreia , Skowronek, Agata, Snyder, Orman L., Sódar, Barbara W., Soekmadji, Carolina , Stahl, Philip D., Stoorvogel, Willem , Stott, Shannon L. , Strasser, Erwin , Tahara, Hidetoshi , Tewari, Muneesh , Timms, Kate , Tiwari, Swasti , Tixeira, Rochelle , Toh, Wei Seong , Tomasini, Richard , Tosar, Juan Pablo , Toxavidis, Vasilis, Urbanelli, Lorena , Vader, Pieter , Balkom, Bas WM van, Grein, Susanne G van der, Deun, Jan Van , Herwijnen, Martijn J. C. van , Keuren‐Jensen, Kendall Van , Niel, Guillaume van , Royen, Martin E. van , Wijnen, André J. van , Vasconcelos, M. Helena , Vechetti, Ivan J. , Vella, Laura J. , Velot, Émilie , Verweij, Frederik J. , Vestad, Beate , Viñas, Jose L. , Visnovitz, Tamás , Vukman, Krisztina V , Wahlgren, Jessica, Watson, Dionysios C. , Wauben, Marca H. M. , Weaver, Alissa M. , Webber, Jason , Weber, Viktoria , Wehman, Ann M. , Welsh, Joshua A , Wheelock, Åsa M. , Wiener, Zoltán , Witte, Leonie , Wolfram, Joy , Xagorari, Angeliki , Xander, Patrícia , Xu, Jing , Yan, Xiaomei , Yin, Hang , Yuana, Yuana, Zappulli, Valentina , Zárubová, Jana , Žėkas, Vytautas , Zhang, Jianye , Zhao, Zezhou , Zickler, Antje M. , Zimmermann, Pascale , Zivkovic, Angela M. , Zocco, Davide, Zuba‐Surma, Ewa , Malhi, Harmeet , Peinado, Héctor , van Wijnen, Andre J , Bergese, Paolo , Kim, Kwang Pyo , Ikezu, Tsuneya , Wolfram, Joy , Lenassi, Metka , Gualerzi, Alice , Nazarenko, Irina , Pink, Ryan , Siljander, Pia R-M , Welsh, Joshua A , Witwer, Kenneth W , Hill, Andrew F , Coyle, Beth , Saugstad, Julie A , Buch, Shilpa J. , Buck, Amy H. , Bussolati, Benedetta , Camussi, Giovanni , Chang, Yu‐Ting , Chen, Chihchen , Chen, Daiwen , Criado, Miriã Ferreira , Das, Saumya , Dieterich, Lothar C. , Dolo, Vincenza , Dominici, Massimo , Falcón‐Pérez, Juan Manuel , Gabrielsson, Susanne , Khvorova, Anastasia , Krasemann, Susanne , Kusuma, Gina Diamanta , Lannigan, Joanne , Laurent, Louise C , Lavieu, Grégory , Lombard, Catherine Anne , Lötvall, Jan , Maas, Sybren L. N. , Mertens, Inge , Minciacchi, Valentina R. , Möller, Andreas , Morales‐Kastresana, Aizea , Mullier, François , Neri, Tommaso , Nieuwland, Rienk , Nimrichter, Leonardo , O’Driscoll, Lorraine , O’Loghlen, Ana , Park, Jaesung , Raimondo, Stefania , Regev‐Rudzki, Neta , Robbins, Paul D. , Saá, Paula , Schiffelers, Raymond Michel , Shetty, Ashok Kumar , Soares, Rodrigo Pedro , Sotillo, Javier , Swift, Simon , Tkach, Mercedes , Torrecilhas, Ana Cláudia , Balkom, Bas W. M. van , Grein, Susanne G. van der, Veit, Tiago Degani , Weiss, Daniel J. , Wendt, Sebastian, Yáñez‐Mó, María , Zheng, Lei , Zheutlin, Alexander R. , Borràs, Francesc E , Martens-Uzunova, Elena S , Buzas, Edit I , Giebel, Bernd , Jones, Jennifer C , Ortiz, Alberto , Greening, David W

Mayo Clinic

Journal of Extracellular Vesicles | November 24, 2018 | Volume: 7 | Issue: 1 | Pages: No page available

10.1080/20013078.2018.1535750 | PMID 30637094 Get It

ABSTRACT The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV‐associated functional activities. Finally, a checklist is provided with summaries of key points.